Fentanyl, Stimulants, Hallucinogens and Other substances
Dear Members: This is the third in a series of communications to provide a summary of the topics discussed at the American Medical Association (AMA) State Advocacy Summit (SAS), which I attended at the beginning of this year. The meeting was packed with enlightening information on a list of topics from a variety of panelists that I want to share with you. The third in my series of communications from the AMA State Advocacy Conference is a discussion on "Fentanyl, Stimulants, Hallucinogens, and Other Substances." There was a very good panel at the State Advocacy Summit on fentanyl, stimulants, hallucinogens, and other substances which have had a devastating impact on in our communities. Read more.

Scope of Practice (AMA State Advocacy Summit)
Dear Members: This is the second in a series of communications to provide a summary of the topics discussed at the American Medical Association (AMA) State Advocacy Summit (SAS), which I attended at the beginning of this year. The meeting was packed with enlightening information on a list of topics from a variety of panelists that I want to share with you. Read more.

Insurance Barriers to Care, AMA State Advocacy Summit 
Dear Members: I had the opportunity to attend the American Medical Association (AMA) State Advocacy Summit, which concluded in not-so-sunny Amelia Island, Florida. The meeting was packed with enlightening information on a list of topics from a variety of panelists. Because of the importance of these issues, I plan a series of communications to the membership over the next several months with a summary of the topics discussed, as well as my thoughts. Read more.